Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New Publication in CCR
Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New Publication in CCR
- AI-based tumor microenvironment classification utilizing Lunit SCOPE IO shows promise for guiding treatment decisions in advanced BTC
- 利用Lunit SCOPE IO的基于人工智能的肿瘤微环境分类显示在指导晚期胆道癌治疗决策方面有希望
SEOUL, South Korea, Sept. 3, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced that Lunit SCOPE IO has demonstrated significant potential in predicting immunotherapy response for patients with advanced biliary tract cancer (BTC), via AI-powered analysis of immune phenotype and tumor-infiltrating lymphocytes (TILs). The groundbreaking study, conducted in collaboration with researchers from Asan Medical Center and Severance Hospital in Seoul, Korea, was recently published in Clinical Cancer Research (CCR), an AACR journal.
2024年9月3日，韩国首尔/PRNewswire/-- 人工智能诊断和治疗领域的领先供应商Lunit (KRX:328130.KQ) 今天宣布，通过对免疫表型和肿瘤浸润淋巴细胞 (TIL) 进行基于人工智能的分析， Lunit SCOPE IO 在预测具有先进胆道癌的免疫治疗反应中显示出重要的潜力。这项突破性研究与韩国首尔的阿山医学中心和西福医院的研究人员合作进行， 最近在《临床癌症研究》(CCR)上发布, 这是AACR杂志
BTC is known for its poor prognosis, with limited treatment options available. While recent studies have shown promise in combining immunotherapy, such as anti-PD-1 inhibitors with standard chemotherapy, there has been a lack of effective predictive tools to guide treatment decisions.
胆道癌以其预后不良、治疗选择有限而闻名。虽然最近的研究显示将免疫治疗与标准化疗，如抗PD-1抑制剂结合，有希望。然而，目前缺乏有效的预测工具来指导治疗决策。
The study analyzed pre-treatment pathology samples (H&E slides) from 339 patients with advanced BTC who received anti-PD-1 monotherapy as second-line or later treatment. Using Lunit SCOPE IO, researchers performed a detailed analysis of the tumor microenvironment, classifying patients' immune phenotypes into three categories: inflamed (high intratumoral TIL), immune-excluded (low intratumoral TIL and high stromal TIL), and immune desert (low TIL overall). Immune phenotypes are an emerging pan-cancer biomarker with support from leaders of the immuno-oncology community.[1]
该研究分析了接受抗PD-1单药治疗作为第二线或更后期治疗的339名患有晚期胆道癌的患者的治疗前病理样本(H&E幻灯片)。利用Lunit SCOPE IO，研究人员对肿瘤微环境进行了详细分析，将患者的免疫表型分为三类: 充血型(高肿瘤内TIL)，免疫被排除型(肿瘤内TIL低且间质TIL高)，免疫沙漠型(整体TIL低)。免疫表型是一种新兴的全癌症生物标志物，在免疫肿瘤学的领导者的支持下得到了广泛认可。[1]
Key findings include:
将AD04与心理社会干预相结合，可能有利于改变酒精使用障碍疾病的观念，增加许多原本没有考虑过该治疗的人的需求。
- Patients classified as having an "inflamed" immune phenotype showed significantly better treatment outcomes compared to those with non-inflamed phenotypes, as consistent with previously published studies.[2]
- The inflamed group demonstrated both longer overall survival (12.6 vs. 5.1 months) and progression-free survival (4.5 vs. 1.9 months), as well as higher overall response rates (27.5% vs. 7.7%).
- Lunit SCOPE IO provided objective and efficient assessment of the tumor microenvironment, overcoming limitations of manual evaluation demonstrating high feasibility for AI-powered analysis of immune phenotype and TIL.
- 对于被分类为具有“炎症”免疫表型的患者，与非炎症表型相比，治疗效果显著更好，这与先前发表的研究结果一致。[2]
- 炎症组表现出更长的总生存期（12.6 vs. 5.1个月）和无进展生存期（4.5 vs. 1.9个月），以及更高的总体反应率（27.5% vs. 7.7%）.
- Lunit SCOPE IO提供了肿瘤微环境的客观高效评估，克服了手动评价的局限性，展示了对于免疫表型和TIL的AI驱动分析的高可行性。
Notably, this study suggests immune phenotyping can serve as a predictive biomarker for possible response to immunotherapy in BTC, addressing a long-standing gap in personalized treatment approaches for this class of cancers with a high unmet need.
值得注意的是，这项研究表明，免疫表型可以作为胆总管癌对免疫治疗可能反应的预测生物标志物，解决了长期以来在高未满足需求的这类癌症的个性化治疗方法中存在的缺口。
"Lunit SCOPE IO represents a significant advancement in the precision medicine landscape for cancer treatment," said Brandon Suh, CEO at Lunit. "By providing a deeper understanding of the tumor microenvironment, particularly immune phenotyping, our AI technology empowers clinicians to make informed treatment decisions, identifying patients most likely to benefit from immunotherapy and opening new avenues for personalized treatment strategies in challenging cancer types."
“Lunit SCOPE IO代表了癌症治疗精准医学领域的重大进展，” Lunit首席执行官Brandon Suh表示。“通过对肿瘤微环境，特别是免疫表型的深入了解，我们的AI技术赋予临床医生做出明智的治疗决策的能力，以确定最可能从免疫治疗中受益的患者，为具有挑战性的癌症类型开辟了个性化治疗策略的新途径。”
About Lunit
关于Lunit
Founded in 2013, Lunit is a medical AI company on a mission to conquer cancer. We harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. Our FDA-cleared Lunit INSIGHT suite for cancer screening serves over 3,500 hospitals and medical institutions across 50+ countries.
成立于2013年，Lunit是一家专注于征服癌症的医疗人工智能公司。我们利用AI技术的医学影像分析和AI生物标记物，确保每位癌症患者的准确诊断和最佳治疗。我们的经FDA认可的癌症筛查Lunit INSIGHt套件服务于50多个国家的3,500多家医院和医疗机构。
Our clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
我们的临床研究已发表在《临床肿瘤学》和《柳叶刀数字医疗》等顶级期刊，并在全球会议如ASCO和RSNA上发表。2024年，Lunit收购了Volpara Health Technologies，为乳腺健康和筛查技术的卓越协同和准确性奠定了基础。总部位于韩国首尔，在全球各地设有办事处，Lunit引领全球抗击癌症的斗争。欢迎了解更多信息。 lunit.io.
[1] The cancer-immunity cycle: Indication, genotype, and immunotype, Immunity, 2023: Link
[2] Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types, JITC, 2024: Link
[1] 癌症免疫循环：指示，基因型和免疫型，免疫，2023年： 连接
[2] 发炎免疫表型预示着多种癌症类型免疫检查点抑制剂治疗的有利临床结果，JITC，2024年： 连接
SOURCE Lunit
来源 Lunit